TGFB1 and pulmonary fibrosis: The existing therapeutic approaches to treat lung fibrosis consist of drugs that aim to control the TGF-β signaling pathway and extracellular matrix accumulation: nintedanib, a tyrosine kinase inhibitor that targets multiple tyrosine kinases, and pirfenidone, an agent that reduces TGF-β signaling pathway with anti-inflammatory actions [3, 4, 44].